FDA grants TiGenix therapy orphan drug designation & more — 5 GI company key notes

Here are five updates on GI companies from the past week:

Advertisement

The FDA granted TiGenix orphan drug designation for Cx601, its lead candidate which treats fistulizing Crohn’s disease.

Apollo Endosurgery entered into a registry funding agreement with the American Gastroenterological Association to develop a flexible endoscopic procedures registry.

Ambu acquired Invendo Medical and its single-use endoscope business for €225 million ($265 million.)

The UK Medicines and Healthcare Products Regulatory Agency approved Norgine B.V.’s bowel cleaning solution Plenvu.

More articles on gastroenterology:
GI leader to know: Dr. Umaprasanna Karnam of Gut Whisperer Center for Digestive Health
Stock market week-in-review for 5 large GI companies — Oct. 16-20
To prevent injury, gastroenterologists should complete more ergonomics training, take breaks

At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.

Advertisement

Next Up in GI & Endoscopy

Advertisement

Comments are closed.